Posted by Michael Wonder on 07 May 2025
Omaveloxolone for the treatment of patients with Friedreich’s ataxia
6 May 2025 - NICE is unable to make a recommendation on the use of omaveloxolone (Skyclarys) for the treatment of patients 16 years of age and older with Friedreich’s ataxia because Biogen withdrew its evidence submission.
NICE will review this decision if Biogen decides to make a new submission.
